News
Simcere, Stanford Medicine Partner on Idiopathic Pulmonary Fibrosis Therapy
Simcere Pharmaceutical and Stanford Medicine join forces to develop innovative therapies for patients with Idiopathic Pulmonary Fibrosis, a chronic, progressive lung disease.

